Robust Clinical Data and Positive Customer Experience with T2Bacteria and T2Candida Panels Highlighted at Recent Medical Meetings

by NASDAQ Market News May 23, 2019

NASDAQ Market News
Click here to email author

Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH

Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial

Ads